Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea

Date: July 17, 2017 Issue #:  1525Summary:  The FDA has approved telotristat ethyl (Xermelo– Lexicon), a tryptophan hydroxylase inhibitor, for use in combination with a somatostatin analog (SSA) for treatment of carcinoid syndrome diarrhea inadequately controlled with SSA therapy alone. Telotristat ethyl is the first oral drug to be approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: lanreotide octreotide Sandostatin Somatuline Autogel Somatuline Depot Telotristat ethyl Xermelo Source Type: research